Abstract:TSC2 negatively regulates Glutaredoxin‐1 (Glrx) hyperactivation in a mTORC1‐independent manner in lymphangioleiomyomatosis (LAM). Abnormal Glrx inhibits reactive oxygen species accumulation and decreases glutathione adducts on nuclear factor‐kappa B p65, which contributed to promoting Cox2 expression and the biosynthesis of PGE2. Increased PGE2 metabolism exacerbates phosphorylation of ERK, which leads to proteasome degradation of Bim and further induces cell survival in LAM. Background Lymphangioleiomyomatosis (LAM) is a female‐predominant interstitial lung disease, characterized by progressive cyst formation and respiratory failure. Clinical treatment with the mTORC1 inhibitor rapamycin could relieve partially the respiratory symptoms, but not curative. It is urgent to illustrate the fundamental mechanisms of TSC2 deficiency to the development of LAM, especially mTORC1‐independent mechanisms. Glutaredoxin‐1 (Glrx), an essential glutathione (GSH)‐dependent thiol‐oxidoreductase, maintains redox homeostasis and participates in various processes via controlling protein GSH adducts. Redox signalling through protein GSH adducts in LAM remains largely elusive. Here, we demonstrate the underlying mechanism of Glrx in the pathogenesis of LAM. Methods 1. Abnormal Glrx expression in various kinds of human malignancies was identified by the GEPIA tumour database, and the expression of Glrx in LAM‐derived cells was detected by real‐time quantitative reverse transcription (RT‐qPCR) and immunoblot. 2. Stable Glrx knockdown cell line was established to evaluate cellular impact. 3. Cell viability was determined by CCK8 assay. 4. Apoptotic cell number and intracellular reactive oxygen species (ROS) level were quantified by flow cytometry. 5. Cox2 expression and PGE2 production were detected to clarify the mechanism of Bim expression modulated by Glrx. 6. S‐glutathionylated p65 was enriched and detected by immunoprecipitation and the direct regulation of Glrx on p65 was determined. 7. The xenograft animal model was established and photon flux was analyzed using IVIS Spectrum. Results In LAM, TSC2 negatively regulated abnormal Glrx expression and activation in a mTORC1‐independent manner. Knockdown of Glrx increased the expression of Bim and the accumulation of ROS, together with elevated S‐glutathionylated proteins, contributing to the induction of apoptotic cell death and inhibited cell proliferation. Knockdown of Glrx in TSC2‐deficient LAM cells increased GSH adducts on nuclear factor‐kappa B p65, which contributed to a decrease in the expression of Cox2 and the biosynthesis of PGE2. Inhibition of PGE2 metabolism attenuated phosphorylation of ERK, which led to the accumulation of Bim, due to the imbalance of its phosphorylation and proteasome degradation. In xenograft tumour models, knockdown of Glrx in TSC2‐deficient LAM cells inhibited tumour growth and increased tumour cell apoptosis. Conclusions Collectively, we provide a novel redox‐dependent mechanism in the pathogenesis of LAM and propose that Glrx may be a beneficial strategy for the treatment of LAM or other TSC‐related diseases.

miR‑124 targets retinoid X receptor α to reduce growth of TSC2‑deficient lymphangioleiomyomatosis.

A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple‐negative breast cancer

MicroRNA-145 Inhibits Growth of Laryngeal Squamous Cell Carcinoma by Targeting the PI3K/Akt Signaling Pathway.

Zoledronic Acid Inhibits TSC2-null Cell Tumor Growth Via RhoA/YAP Signaling Pathway in Mouse Models of Lymphangioleiomyomatosis.

Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment

Decreased Mir-124 Contributes to the Epithelial-Mesenchymal Transition Phenotype Formation of Lung Adenocarcinoma Cells Via Targeting Enhancer of Zeste Homolog 2.

Glutaredoxin‐1 promotes lymphangioleiomyomatosis progression through inhibiting Bim‐mediated apoptosis via COX2/PGE2/ERK pathway

MiR-124 Inhibits Cell Proliferation, Migration and Invasion by Directly Targeting SOX9 in Lung Adenocarcinoma.

Downregulated Mir-1247-5p Associates with Poor Prognosis and Facilitates Tumor Cell Growth Via DVL1/Wnt/β-catenin Signaling in Breast Cancer

Mir-124 Inhibits Progression of Hepatocarcinoma by Targeting KLF4 and Promises a Novel Diagnostic Marker

Downregulation of microRNA-224-3p Hampers Retinoblastoma Progression via Activation of the Hippo-YAP Signaling Pathway by Increasing LATS2

Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells

miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipoma

MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma.

Inhibition of Lhx2 by Mir-124 Suppresses Cellular Migration and Invasion in Non-Small Cell Lung Cancer

Sirolimus Decreases Circulating Lymphangioleiomyomatosis Cells in Patients with Lymphangioleiomyomatosis

MicroRNA-124 Functions as a Tumor Suppressor by Regulating CDH2 and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.

Single-cell multiomic analysis identifies a HOX-PBX gene network regulating the survival of lymphangioleiomyomatosis cells

MicroRNA-124 Inhibits Cellular Proliferation and Invasion by Targeting Ets-1 in Breast Cancer

MicroRNA-124 Regulates TRAF6 Expression and Functions As an Independent Prognostic Factor in Colorectal Cancer

Downregulation of Mir-125B-5p and Its Prospective Molecular Mechanism in Lung Squamous Cell Carcinoma.